文献速递骨肿瘤

布比卡因与利多卡因诱导骨肉瘤肿瘤细胞凋亡

Bupivacaine and Lidocaine Induce Apoptosis in Osteosarcoma Tumor Cells.
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

研究评估布比卡因和利多卡因对UMR-108与MNNG/HOS两种骨肉瘤细胞系的作用,发现两药均以剂量和时间依赖方式导致细胞死亡,且死亡与凋亡一致,涉及内源性凋亡通路;作者认为这些发现为在体内评估这些药物提供了基础,建议先在小动物中研究。

要点

  • 布比卡因和利多卡因均以剂量和时间依赖方式降低两种骨肉瘤细胞系的活力
  • 细胞死亡与凋亡一致,内源性凋亡通路参与其中
  • 作者认为这些发现为在体内评估这些药物提供了基础

核心结论

  • 布比卡因和利多卡因以剂量和时间依赖方式导致骨肉瘤细胞死亡,细胞死亡与凋亡一致,涉及内源性凋亡通路。
  • 作者认为这些发现为在体内评估这些药物提供了基础。
  • 作者建议在小动物中进行研究,以确定临床相关剂量在体内是否有类似效果。
  • 作者提出在人体中可用这些药物的标准剂量进行活检,以观察确定切除时活检通道污染是否有差异。

研究设计与样本

  • 体外研究,选用UMR-108和MNNG/HOS两种骨肉瘤细胞系。
  • 两种细胞系分别暴露于布比卡因(0.27、0.54、1.08、2.16、4.33和8.66 mM)和利多卡因(0.66、1.33、5.33、10.66、21.32和42.64 mM)24小时、48小时和72小时。
  • 上述浓度由初步实验确定,初步实验发现两种细胞系的布比卡因中位有效剂量为1.4 mM,利多卡因中位有效剂量为7.0 mM。
  • 采用微培养四唑盐法和集落形成实验确定细胞死亡,通过相差显微镜图像、流式细胞术、DNA片段化和活性氧(ROS)评估凋亡诱导,通过蛋白电泳和Western blot分析通路。
  • 所有检测均设三个重复并与pH调整的对照比较,定量结果分析未设盲。

主要发现

  • 暴露于布比卡因24小时,UMR-108细胞活力在1.08 mM时降低6 ± 0.75%(95% CI 2.9至9.11;p = 0.01),在2.16 mM时降低89.67 ± 1.5%(95% CI 82.2至95.5;p < 0.001)。
  • 相同条件下,MNNG/HOS细胞活力以类似方式降低。
  • 24小时后,暴露于5.33 mM利多卡因的UMR-108和MNNG/HOS细胞活力分别降低25.33 ± 8.3%(95% CI 2.1至48.49;p = 0.03)和39.33 ± 3.19%(95% CI 30.46至48.21;p < 0.001),在10.66 mM时分别降低90.67 ± 0.66%(95% CI 88.82至92.52;p < 0.001)和81.6 ± 0.47%(95% CI 79.69至82.31;p < 0.001)。
  • 72小时后,两种细胞系的活力进一步降低。
  • Annexin-V阳性证实的凋亡UMR-108和MNNG/HOS细胞百分比较对照增加:布比卡因1.08 mM时为21.3 ± 2.82(95% CI 16.25至26.48;p < 0.001)和21.23 ± 3.23%(95% CI 12.2至30.2;p = 0.003),利多卡因5.33 mM时为25.15 ± 4.38(95% CI 12.9至37.3;p = 0.004)和9.11 ± 1.74(95% CI 4.35至13.87;p = 0.006)。

关键数值与推荐

  • 布比卡因浓度:0.27、0.54、1.08、2.16、4.33和8.66 mM;利多卡因浓度:0.66、1.33、5.33、10.66、21.32和42.64 mM;暴露时间24、48和72小时。
  • 初步实验测得两种细胞系的布比卡因中位有效剂量为1.4 mM,利多卡因中位有效剂量为7.0 mM。
  • UMR-108细胞暴露于布比卡因1.08 mM 24小时活力降低6 ± 0.75%(95% CI 2.9至9.11;p = 0.01),2.16 mM时降低89.67 ± 1.5%(95% CI 82.2至95.5;p < 0.001)。
  • UMR-108和MNNG/HOS细胞暴露于利多卡因5.33 mM 24小时活力分别降低25.33 ± 8.3%(95% CI 2.1至48.49;p = 0.03)和39.33 ± 3.19%(95% CI 30.46至48.21;p < 0.001),10.66 mM时分别降低90.67 ± 0.66%(95% CI 88.82至92.52;p < 0.001)和81.6 ± 0.47%(95% CI 79.69至82.31;p < 0.001)。
  • 凋亡细胞百分比较对照增加:布比卡因1.08 mM时UMR-108为21.3 ± 2.82(95% CI 16.25至26.48;p < 0.001),MNNG/HOS为21.23 ± 3.23%(95% CI 12.2至30.2;p = 0.003);利多卡因5.33 mM时UMR-108为25.15 ± 4.38(95% CI 12.9至37.3;p = 0.004),MNNG/HOS为9.11 ± 1.74(95% CI 4.35至13.87;p = 0.006)。

临床怎么用

  • 作者认为布比卡因和利多卡因可能因其诱导和增强凋亡的能力而用于局部骨肉瘤治疗。
  • 作者建议在骨肉瘤治疗中常规使用这些药物时,可将结局数据与对照进行比较评估。
  • 作者建议进行进一步的小动物研究,以确定肿瘤内注射、隔离肢体灌注或其他治疗方式是否可行。
  • 作者提出在人体中可用这些药物的标准剂量进行活检,以观察确定切除时活检通道污染是否有差异。

局限性

  • 定量结果分析未设盲。
  • 作者结论指出这些发现为在体内评估这些药物提供了基础,并建议在小动物中进行研究以确定临床相关剂量在体内是否有类似效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteosarcoma is the most common type of bone cancer in adolescents. There have been no significant improvements in outcomes since chemotherapy was first introduced. Bupivacaine and lidocaine have been shown to be toxic to certain malignancies. This study evaluates the effect of these medications on two osteosarcoma cell lines. QUESTIONS/PURPOSES: (1) Does incubation of osteosarcoma cells with bupivacaine or lidocaine result in cell death? (2) Does this result from an apoptotic mechanism? (3) Is a specific apoptotic pathway implicated? METHODS: Two cell lines were chosen to account for the inherent heterogeneity of osteosarcoma. UMR-108 is a transplantable cell line that has been used in multiple studies as a primary tumor. MNNG/HOS has a high metastatic rate in vivo. Both cell lines were exposed bupivacaine (0.27, 0.54, 1.08, 2.16, 4.33 and 8.66 mM) and lidocaine (0.66, 1.33, 5.33, 10.66, 21.32 and 42.64 mM) for 24 hours, 48 hours, and 72 hours. These concentrations were determined by preliminary experiments that found the median effective dose was 1.4 mM for bupivacaine and 7.0 mM for lidocaine in both cell lines. Microculture tetrazolium and colony formation assay determined whether cell death occurred. Apoptosis induction was evaluated by phase-contrast micrographs, flow cytometry, DNA fragmentation and reactive oxygen species (ROS). The underlying pathways were analyzed by protein electrophoresis and Western blot. All testing was performed in triplicate and compared with pH-adjusted controls. Quantitative results were analyzed without blinding. RESULTS: Both medications caused cell death in a dose- and time-dependent manner. Exposure to bupivacaine for 24 hours reduced viability of UMR-108 cells by 6 ± 0.75% (95% CI 2.9 to 9.11; p = 0.01) at 1.08 mM and 89.67 ± 1.5% (95% CI 82.2 to 95.5; p < 0.001) at 2.16 mM. Under the same conditions, MNNG/HOS viability was decreased in a similar fashion. After 24 hours, the viability of UMR-108 and MNNG/HOS cells exposed to 5.33 mM of lidocaine decreased by 25.33 ± 8.3% (95% CI 2.1 to 48.49; p = 0.03) and 39.33 ± 3.19% (95% CI 30.46 to 48.21; p < 0.001), respectively, and by 90.67 ± 0.66% (95% CI 88.82 to 92.52; p < 0.001) and 81.6 ± 0.47% (95% CI 79.69 to 82.31; p < 0.001) at 10.66 mM, respectively. After 72 hours, the viability of both cell lines was further reduced. Cell death was consistent with apoptosis based on cell morphology, total number of apoptotic cells and DNA fragmentation. The percentage increase of apoptotic UMR-108 and MNNG/HOS cells confirmed by Annexin-V positivity compared with controls was 21.3 ± 2.82 (95% CI 16.25 to 26.48; p < 0.001) and 21.23 ± 3.23% (95% CI 12.2 to 30.2; p = 0.003) for bupivacaine at 1.08 mM and 25.15 ± 4.38 (95% CI 12.9 to 37.3; p = 0.004) and 9.11 ± 1.74 (95% CI 4.35 to 13.87; p = 0.006) for lidocaine at 5.33 mM. The intrinsic apoptotic pathway was involved as the expression of Bcl-2 and survivin were down-regulated, and Bax, cleaved caspase-3 and cleaved poly (ADP-ribose) polymerase-1 were increased. ROS production increased in the UMR-108 cells but was decreased in the MNNG/HOS cells. CONCLUSION: These findings provide a basis for evaluating these medications in the in vivo setting. Studies should be performed in small animals to determine if clinically relevant doses have a similar effect in vivo. In humans, biopsies could be performed with standard doses of these medications to see if there is a difference in biopsy tract contamination on definitive resection. CLINICAL RELEVANCE: Bupivacaine and lidocaine could potentially be used for their ability to induce and enhance apoptosis in local osteosarcoma treatment. Outcome data when these medications are used routinely during osteosarcoma treatment can be evaluated compared with controls. Further small animal studies should be performed to determine if injection into the tumor, isolated limb perfusion, or other modalities of treatment are viable.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Mirshahidi S, Shields TG, de Necochea-Campion R, et al. Bupivacaine and Lidocaine Induce Apoptosis in Osteosarcoma Tumor Cells. Clin Orthop Relat Res. 2021. PMID: 33009230. doi:10.1097/CORR.0000000000001510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。